Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • ObjectiveTo develop guidance on the use of coronavirus disease 2019 (COVID-19) vaccines in patients with autoimmune rheumatic diseases (ARD).MethodsThe Canadian Rheumatology Association (CRA) formed a multidisciplinary panel including rheumatologists, researchers, methodologists, vaccine experts, and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Outcomes were prioritized according to their importance for patients and clinicians. Evidence from the COVID-19 clinical trials was summarized. Indirect evidence for non–COVID-19 vaccines in ARD was also considered. The GRADE evidence-to-decision (EtD) framework was used to develop a recommendation for the use of the 4 COVID-19 vaccines approved in Canada as of March 25, 2021 (BNT162b2, mRNA-1273, ChAdOx1, and Ad26.COV2.S), over 4 virtual panel meetings.ResultsThe CRA guideline panel suggests using COVID-19 vaccination in persons with ARD. The panel unanimously agreed that for the majority of patients, the potential health benefits of vaccination outweigh the potential harms in people with ARDs. The recommendation was graded as conditional because of low or very low certainty of the evidence on the effects in the population of interest, primarily due to indirectness and imprecise effect estimates. The panel felt strongly that persons with autoimmune rheumatic diseases who meet local eligibility should not be required to take additional steps compared to people without ARDs to obtain their vaccination. Guidance on medications, implementation, monitoring of vaccine uptake, and research priorities are also provided.ConclusionThis recommendation will be updated over time as new evidence emerges, with the latest recommendation, evidence summaries, and EtD available on the CRA website.

authors

  • Hazlewood, Glen S
  • Pardo, Jordi Pardo
  • Barnabe, Cheryl
  • Schieir, Orit
  • Barber, Claire EH
  • Bernatsky, Sasha
  • Colmegna, Ines
  • Hitchon, Carol
  • Loeb, Mark
  • Mertz, Dominik
  • Proulx, Laurie
  • Richards, Dawn P
  • Scuccimarri, Rosie
  • Tugwell, Peter
  • Schunemann, Holger
  • Mirza, Reza D
  • Zhou, Alan L
  • Nikolic, Roko PA
  • Thomas, Megan
  • Chase, Helena
  • Ejaredar, Maede
  • Nieuwlaat, Robby

publication date

  • August 2021